Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [Internet]. 31 déc. 2025 [cité 14 avr. 2026];40(2):251-62. Disponible à: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001